Standardized assays to monitor drug sensitivity in hematologic cancers
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Standardized assays to monitor drug sensitivity in hematologic cancers. / Ayuda-Durán, Pilar; Hermansen, Johanne U.; Giliberto, Mariaserena; Yin, Yanping; Hanes, Robert; Gordon, Sandra; Kuusanmäki, Heikki; Brodersen, Andrea M.; Andersen, Aram N.; Taskén, Kjetil; Wennerberg, Krister; Enserink, Jorrit M.; Skånland, Sigrid S.
In: Cell Death Discovery, Vol. 9, 435, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Standardized assays to monitor drug sensitivity in hematologic cancers
AU - Ayuda-Durán, Pilar
AU - Hermansen, Johanne U.
AU - Giliberto, Mariaserena
AU - Yin, Yanping
AU - Hanes, Robert
AU - Gordon, Sandra
AU - Kuusanmäki, Heikki
AU - Brodersen, Andrea M.
AU - Andersen, Aram N.
AU - Taskén, Kjetil
AU - Wennerberg, Krister
AU - Enserink, Jorrit M.
AU - Skånland, Sigrid S.
N1 - Publisher Copyright: © 2023, The Author(s).
PY - 2023
Y1 - 2023
N2 - The principle of drug sensitivity testing is to expose cancer cells to a library of different drugs and measure its effects on cell viability. Recent technological advances, continuous approval of targeted therapies, and improved cell culture protocols have enhanced the precision and clinical relevance of such screens. Indeed, drug sensitivity testing has proven diagnostically valuable for patients with advanced hematologic cancers. However, different cell types behave differently in culture and therefore require optimized drug screening protocols to ensure that their ex vivo drug sensitivity accurately reflects in vivo drug responses. For example, primary chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) cells require unique microenvironmental stimuli to survive in culture, while this is less the case for acute myeloid leukemia (AML) cells. Here, we present our optimized and validated protocols for culturing and drug screening of primary cells from AML, CLL, and MM patients, and a generic protocol for cell line models. We also discuss drug library designs, reproducibility, and quality controls. We envision that these protocols may serve as community guidelines for the use and interpretation of assays to monitor drug sensitivity in hematologic cancers and thus contribute to standardization. The read-outs may provide insight into tumor biology, identify or confirm treatment resistance and sensitivity in real time, and ultimately guide clinical decision-making.
AB - The principle of drug sensitivity testing is to expose cancer cells to a library of different drugs and measure its effects on cell viability. Recent technological advances, continuous approval of targeted therapies, and improved cell culture protocols have enhanced the precision and clinical relevance of such screens. Indeed, drug sensitivity testing has proven diagnostically valuable for patients with advanced hematologic cancers. However, different cell types behave differently in culture and therefore require optimized drug screening protocols to ensure that their ex vivo drug sensitivity accurately reflects in vivo drug responses. For example, primary chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) cells require unique microenvironmental stimuli to survive in culture, while this is less the case for acute myeloid leukemia (AML) cells. Here, we present our optimized and validated protocols for culturing and drug screening of primary cells from AML, CLL, and MM patients, and a generic protocol for cell line models. We also discuss drug library designs, reproducibility, and quality controls. We envision that these protocols may serve as community guidelines for the use and interpretation of assays to monitor drug sensitivity in hematologic cancers and thus contribute to standardization. The read-outs may provide insight into tumor biology, identify or confirm treatment resistance and sensitivity in real time, and ultimately guide clinical decision-making.
U2 - 10.1038/s41420-023-01722-5
DO - 10.1038/s41420-023-01722-5
M3 - Journal article
C2 - 38040674
AN - SCOPUS:85178234764
VL - 9
JO - Cell Death Discovery
JF - Cell Death Discovery
SN - 2058-7716
M1 - 435
ER -
ID: 378951233